Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired DexCom, Inc. ("DexCom") (NASDAQ: DXCM) securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”).
DexCom is a medical device company primarily focused on the design, development, and commercialization of continuous glucose monitoring (“CGM”) systems for the management of diabetes and metabolic health. DexCom’s products include, among others, the G6 and G7 CGM systems, which DexCom launched in 2018 and 2023, respectively. The G7 is DexCom’s flagship product and, accordingly, its commercial success is of paramount importance to both investors and DexCom.
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to its G6 and G7 CGM systems that were unauthorized by the FDA; (2) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (3) DexCom’s purported enhancements to the G7, as well as the device’s reliability, accuracy, and functionality, were overstated; (4) DexCom downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (5) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (6) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
On December 26, 2025, Motions to Appoint Lead Plaintiff and Lead Counsel were filed. This action is ongoing.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.